Amelia M. Lias

Amelia M. Lias

Auto-generated profile, based on publicly available information

Amelia M. Lias

Imperial College London

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
RRRobert J. Ragotte
Robert J. Ragotte
DPDavid Pulido
David Pulido
ALAmelia M. Lias
Amelia M. Lias
DQDoris Quinkert
Doris Quinkert
DADaniel G. W. Alanine
Daniel G. W. Alanine
SDSimon Draper
Simon Draper
Understanding mechanisms of antibody synergy is important for vaccine design and antibody cocktail development. Examples of synergy between antibodies are well-documented, but the mechanisms underlying these relationships often remain poorly understood. The leading blood-stage malaria vaccine candidate, CyRPA, is essential for invasion of Plasmodium falciparum into human erythrocytes. Here we present a panel of anti-CyRPA monoclonal antibodies that strongly inhibit parasite growth in in vitro assays. Structural studies show that growth-inhibitory antibodies bind epitopes on a single face of CyRPA. We also show that pairs of non-competing inhibitory antibodies have strongly synergistic growth-inhibitory activity. These antibodies bind to neighbouring epitopes on CyRPA and form lateral, heterotypic interactions which slow antibody dissociation. We predict that such heterotypic interactions will be a feature of many immune responses. Immunogens which elicit such synergistic antibody mixtures could increase the potency of vaccine-elicited responses to provide robust and long-lived immunity against challenging disease targets.

12 July 2023 in Science Translational Medicine
Verified
Journal Article
Open access
MHMimi M. Hou
Mimi M. Hou
JBJordan R. Barrett
Jordan R. Barrett
YTYrene Themistocleous
Yrene Themistocleous
TRThomas A. Rawlinson
Thomas A. Rawlinson
ADAbabacar Diouf
Ababacar Diouf
SDSimon Draper
Simon Draper
There are no licensed vaccines against Plasmodium vivax . We conducted two phase 1/2a clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vectors as well as a protein and adjuvant formulation (PvDBPII/Matrix-M) were tested in both a standard and a delayed dosing regimen. Volunteers underwent controlled human malaria infection (CHMI) after their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparisons of parasite multiplication rates in the blood. PvDBPII/Matrix-M, given in a delayed dosing regimen, elicited the highest antibody responses and reduced the mean parasite multiplication rate after CHMI by 51% ( n = 6) compared with unvaccinated controls ( n = 13), whereas no other vaccine or regimen affected parasite growth. Both viral-vectored and protein vaccines were well tolerated and elicited expected, short-lived adverse events. Together, these results support further clinical evaluation of the PvDBPII/Matrix-M P. vivax vaccine.

7 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
BWBarnabas G. Williams
Barnabas G. Williams
LKLloyd D. W. King
Lloyd D. W. King
DPDavid Pulido
David Pulido
DQDoris Quinkert
Doris Quinkert
ALAmelia M. Lias
Amelia M. Lias
SDSimon Draper
Simon Draper
Reticulocyte-binding protein homologue 5 (RH5), a leading blood-stage Plasmodium falciparum malaria vaccine target, interacts with cysteine-rich protective antigen (CyRPA) and RH5-interacting protein (RIPR) to form an essential heterotrimeric “RCR-complex”. We investigate whether RCR-complex vaccination can improve upon RH5 alone. Using monoclonal antibodies (mAbs) we show that parasite growth-inhibitory epitopes on each antigen are surface-exposed on the RCR-complex and that mAb pairs targeting different antigens can function additively or synergistically. However, immunisation of female rats with the RCR-complex fails to outperform RH5 alone due to immuno-dominance of RIPR coupled with inferior potency of anti-RIPR polyclonal IgG. We identify that all growth-inhibitory antibody epitopes of RIPR cluster within the C-terminal EGF-like domains and that a fusion of these domains to CyRPA, called “R78C”, combined with RH5, improves the level of in vitro parasite growth inhibition compared to RH5 alone. These preclinical data justify the advancement of the RH5.1 + R78C/Matrix-M™ vaccine candidate to Phase 1 clinical trial.

2 September 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
THThomas E Harrison
Thomas E Harrison
NANawsad Alam
Nawsad Alam
BFBrendan Farrell
Brendan Farrell
DQDoris Quinkert
Doris Quinkert
ALAmelia M Lias
Amelia M Lias
MHMatthew K Higgins
Matthew K Higgins
There is an urgent need for improved malaria vaccine immunogens. Invasion of erythrocytes by Plasmodium falciparum is essential for its life cycle, preceding symptoms of disease and parasite transmission. Antibodies which target PfRH5 are highly effective at preventing erythrocyte invasion and the most potent growth-inhibitory antibodies bind a single epitope. Here we use structure-guided approaches to design a small synthetic immunogen, RH5-34EM which recapitulates this epitope. Structural biology and biophysics demonstrate that RH5-34EM is correctly folded and binds neutralising monoclonal antibodies with nanomolar affinity. In immunised rats, RH5-34EM induces PfRH5-targeting antibodies that inhibit parasite growth. While PfRH5-specific antibodies were induced at a lower concentration by RH5-34EM than by PfRH5, RH5-34EM induced antibodies that were a thousand-fold more growth-inhibitory as a factor of PfRH5-specific antibody concentration. Finally, we show that priming with RH5-34EM and boosting with PfRH5 achieves the best balance between antibody quality and quantity and induces the most effective growth-inhibitory response. This rationally designed vaccine immunogen is now available for use as part of future malaria vaccines, alone or in combination with other immunogens.

30 May 2022 in medRxiv
Verified
Preprint
Open access
PDF file
MHMimi M. Hou
Mimi M. Hou
JBJordan R. Barrett
Jordan R. Barrett
YTYrene Themistocleous
Yrene Themistocleous
TRThomas A. Rawlinson
Thomas A. Rawlinson
ADAbabacar Diouf
Ababacar Diouf
SDSimon Draper
Simon Draper
Background: There are no licensed vaccines against Plasmodium vivax , the most common cause of malaria outside of Africa. Methods: We conducted two Phase I/IIa clinical trials to assess the safety, immunogenicity and efficacy of two vaccines targeting region II of P. vivax Duffy-binding protein (PvDBPII). Recombinant viral vaccines (using ChAd63 and MVA vectors) were administered at 0, 2 months or in a delayed dosing regimen (0, 17, 19 months), whilst a protein/adjuvant formulation (PvDBPII/Matrix-M™) was administered monthly (0, 1, 2 months) or in a delayed dosing regimen (0, 1, 14 months). Delayed regimens were due to trial halts during the COVID-19 pandemic. Volunteers underwent heterologous controlled human malaria infection (CHMI) with blood-stage P. vivax parasites at 2-4 weeks following their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparison of parasite multiplication rate (PMR) in blood post-CHMI, modelled from parasitemia measured by quantitative polymerase-chain-reaction (qPCR). Results: Thirty-two volunteers were enrolled and vaccinated (n=16 for each vaccine). No safety concerns were identified. PvDBPII/Matrix-M™, given in the delayed dosing regimen, elicited the highest antibody responses and reduced the mean PMR following CHMI by 51% (range 36-66%; n=6) compared to unvaccinated controls (n=13). No other vaccine or regimen impacted parasite growth. In vivo growth inhibition of blood-stage P. vivax correlated with functional antibody readouts of vaccine immunogenicity. Conclusions: Vaccination of malaria-naïve adults with a delayed booster regimen of PvDBPII/ Matrix-M™ significantly reduces the growth of blood-stage P. vivax . Funded by the European Commission and Wellcome Trust; VAC069, VAC071 and VAC079 ClinicalTrials.gov numbers NCT03797989 , NCT04009096 and NCT04201431 .

24 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
GAGul Afshan
Gul Afshan
NTNicole Tsui
Nicole Tsui
HJHumera Javed
Humera Javed
TKTehmina Kazmi
Tehmina Kazmi
ENEmma Ndagire
Emma Ndagire
TPTom Parks
Tom Parks
The lack of specific diagnostic tests for acute rheumatic fever (ARF) and its consequence rheumatic heart disease (RHD) is a key barrier to effective control of these diseases in low resource settings. Prothymosin alpha (PTA) and immunoglobulin G3 (IgG3) have recently been proposed as ARF biomarkers, although studies of these markers have so far been limited to single populations. Consequently, we evaluated PTA and IgG3 in patients with ARF, RHD and controls from studies set in Pakistan and Uganda.